Participants with Treatment-emergent Adverse Experiences Up to Day 169 [clinicaltrials_resource:27168a72006b7143b12910030cfb7638]

Participants with Treatment-emergent Adverse Experiences Up to Day 169 [clinicaltrials_resource:27168a72006b7143b12910030cfb7638]

BSAP is a biomarker of bone formation.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:27168a72006b7143b12910030cfb7638
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma [clinicaltrials:NCT00747123]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Participants with Treatment-emergent Adverse Experiences Up to Day 169 [clinicaltrials_resource:27168a72006b7143b12910030cfb7638]

BSAP is a biomarker of bone formation.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:27168a72006b7143b12910030cfb7638
Bio2RDF identifier
27168a72006b7143b12910030cfb7638
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:27168a72006b7143b12910030cfb7638
measure [clinicaltrials_vocabulary:measure]
Participants with Treatment-emergent Adverse Experiences
time frame [clinicaltrials_vocabulary:time-frame]
description
BSAP is a biomarker of bone formation.
identifier
clinicaltrials_resource:27168a72006b7143b12910030cfb7638
title
Participants with Treatment-emergent Adverse Experiences Up to Day 169
@en
inDataset
type
label
Participants with Treatment-em ...... 68a72006b7143b12910030cfb7638]
@en